We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Katie Verb Katie Verb is a director in the Policy and Research Department at PhRMA. Her primary focus is access in Medicare Part B and emerging therapy reimbursement, including biosimilar, cell, and gene therapies. Prior to joining PhRMA, Katie led the policy and government relations team at a rare-disease patient advocacy organization where she worked on ensuring access for patients with Medicare, Medicaid and private insurance.
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....